相关实验视频

Updated: Jul 6, 2026

Detection of Architectural Distortion in Prior Mammograms via Analysis of Oriented Patterns

Detection of Architectural Distortion in Prior Mammograms via Analysis of Oriented Patterns

Published on: August 30, 2013

乳腺癌查的成本效益使用加拿大的数字乳腺扫描在加拿大

Anna N Wilkinson¹, James G Mainprize², Martin J Yaffe²

¹Family Medicine, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.

JAMA network open

|January 2, 2025

概括

在40岁开始进行乳腺癌查,而不是50岁,可以改善结果并节省成本. 年度查提供了最好的结果,证明数字造乳镜是降低乳腺癌死亡率的经济有效工具.

科学领域:

卫生经济学卫生经济学
在瘤学瘤学.
公共卫生公共卫生

背景情况:

乳腺癌治疗的不断发展改善了结果,但增加了财务负担.
乳房扫描查与现代治疗相结合的成本效益仍然不清楚.

研究的目的:

评估基于人口的乳腺癌查在当前治疗标准的成本效益.
评估不同查计划对临床结果和治疗成本的影响.

主要方法:

在经济评估中使用了OncoSim-乳腺微型模拟模型.
模拟了一个从1975年到99岁的出生队列,比较了五种查场景.
纳入2023年基于活动的乳腺癌治疗成本数据在加拿大安大略省.

主要成果:

与50岁开始相比,在40岁开始的查改善了结果 (避免死亡,增加寿命,获得质量调整寿命) 并降低了治疗成本.
从40-74岁开始的两年一次查节省了成本,而不是从50-74岁开始的两年一次查.
从40-74岁开始的年度查是具有成本效益的,产生了最好的结果.

结论:

乳腺扫描查,特别是当早些时候开始时,是一种降低乳腺癌死亡率的经济有效方法.
对于单一支付医疗保健系统,建议增加对查计划的投资.
数字造乳镜是减少乳腺癌死亡率的宝贵工具.

更多相关视频

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Published on: December 15, 2014

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

相关概念视频

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...